OncoMatch/Clinical Trials/NCT07010120
A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell Carcinoma
Is NCT07010120 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Lysogenic HSV virus. and Tislelizumab for hnscc.
Treatment: Tislelizumab · Afatinib · Lysogenic HSV virus. — Evaluation of the safety and tolerability of immune-targeted therapy combined with neoadjuvant therapy with lysogenic HSV virus for patients with surgically resectable squamous carcinoma of the head and neck.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: HPV negative
Required: HPV positive
Disease stage
Required: Stage III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
prior use of PD-1 antibody
Cannot have received: anti-PD-L1 therapy
prior use of PD-L1 antibody
Cannot have received: anti-CTLA-4 therapy
prior use of CTLA-4 antibody
Cannot have received: EGFR-targeted therapy
prior use of EGFR antibody, or EGFR-TKI
Cannot have received: anti-tumor vaccine
received an anti-tumor vaccine
Lab requirements
Blood counts
adequate organ and bone marrow function as defined below
Kidney function
adequate organ and bone marrow function as defined below
Liver function
adequate organ and bone marrow function as defined below
Cardiac function
abnormal class II or higher cardiac function (NYHA criteria), ischemic heart disease (e.g., myocardial infarction or angina pectoris), clinically significant supraventricular or ventricular arrhythmia with echocardiographic ejection fraction <50%; QTc interval, >450 msec in men and >470 msec in women; and an abnormal electrocardiogram that, in the opinion of the investigator, poses an experimental drug There is an additional risk
Have adequate organ and bone marrow function as defined below; ... abnormal class II or higher cardiac function (NYHA criteria), ischemic heart disease (e.g., myocardial infarction or angina pectoris), clinically significant supraventricular or ventricular arrhythmia with echocardiographic ejection fraction <50%; QTc interval, >450 msec in men and >470 msec in women; and an abnormal electrocardiogram that, in the opinion of the investigator, poses an experimental drug There is an additional risk
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify